Agios Pharmaceuticals Files 8-K Report
Ticker: AGIO · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Agios Pharma filed a routine 8-K, no major news.
AI Summary
On January 3, 2025, Agios Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a current report and does not appear to disclose any specific material events or transactions requiring immediate public disclosure beyond its routine filing status.
Why It Matters
This filing indicates Agios Pharmaceuticals is up-to-date with its regulatory reporting requirements with the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report and does not contain any new material information that would typically impact stock price or indicate significant risk.
Key Numbers
- 001-36014 — Commission File Number (Identifies the company's SEC filing history.)
- 26-0662915 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- 88 Sidney Street, Cambridge, MA 02139 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to serve as a Current Report, indicating that Agios Pharmaceuticals, Inc. is fulfilling its regulatory obligations to report material information to the SEC.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is January 3, 2025.
Where are Agios Pharmaceuticals, Inc.'s principal executive offices located?
Agios Pharmaceuticals, Inc.'s principal executive offices are located at 88 Sidney Street, Cambridge, MA 02139.
What is the company's Commission File Number?
The company's Commission File Number is 001-36014.
Does this 8-K filing disclose any specific material events?
Based on the provided text, this 8-K filing is categorized as a 'Regulation FD Disclosure' and a 'Current Report' without detailing specific material events that would typically be found in other 8-K items (e.g., Item 1.01, 1.02, 2.01).
Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2025-01-06 06:36:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AGIO Nasdaq Global Select
Filing Documents
- d911895d8k.htm (8-K) — 25KB
- 0001193125-25-001809.txt ( ) — 140KB
- agio-20250103.xsd (EX-101.SCH) — 3KB
- agio-20250103_lab.xml (EX-101.LAB) — 17KB
- agio-20250103_pre.xml (EX-101.PRE) — 11KB
- d911895d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: January 6, 2025 By: /s/ Brian Goff Brian Goff Chief Executive Officer